| Date | Product | Disease | Phase | Company | Therapeutic area |
|---|---|---|---|---|---|
| 2016-10-11 | dusquetide (SGX942) | macrophage activation syndrome | Soligenix (USA - NJ) | Rare diseases | |
| 2016-10-10 | EC1169 | metastatic castration-resistant prostate cancer (mCRPC) | 1 | Endocyte (USA - IN) | Cancer - Oncology |
| 2016-10-10 | EC1456 | non-small cell lung cancer (NSCLC) | 1 | Endocyte (USA - IN) | Cancer - Oncology |
| 2016-10-10 | microcrystalline tyrosine (MCT) | preclinical | Allergy Therapeutics (UK) | Technology - Services | |
| 2016-10-10 | vantictumab (anti-Fzd7, OMP-18R5) | pancreatic cancer | 1 | Bayer Healthcare (Germany) Oncomed Pharmaceuticals (USA) | Cancer - Oncology |
| 2016-10-10 | durvalumab (MEDI4736) and ISIS-STAT3Rx (AZD9150) or AZD5069 | metastatic squamous cell carcinoma of the head and neck | 1-2 | AstraZeneca (UK) | Cancer - Oncology |
| 2016-10-10 | ipafricept (OMP- 54F28 - Fzd8-Fc) | advanced solid tumor cancers | 1b | Bayer Healthcare (Germany) OncoMed Pharmaceuticals (USA - CA) | Cancer - Oncology |
| 2016-10-10 | PM01183 (lurbinectidin) | breast cancer | 2 | PharmaMar (Spain) | Cancer - Oncology |
| 2016-10-10 | RetinoStat® | neovascular “wet” age-related macular degeneration (AMD) | 1 | Oxford BioMedica (UK) | Ophtalmological diseases |
| 2016-10-10 | Prostvac® (rilimogene) and ipilimumab (Yervoy®) | prostate cancer | 2 | Bavarian Nordic (Denmark) University of California, San Francisco (UCSF) (USA - CA) | Cancer - Oncology |
| 2016-10-09 | Tecentriq® (atezolizumab) (MPDL3280A) | non-squamous non-small cell lung cancer (NSCLC) | 3 | Roche (Switzerland) | Cancer - Oncology |
| 2016-10-09 | Zykadia® - LDK378 (ceritinib) | anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) | 2 | Novartis (Switzerland) | Cancer - Oncology |
| 2016-10-09 | lirilumab or IPH2102/BMS-986015 in combination with nivolumab or Anti-PD-1 (BMS-936558) | advanced solid tumors | 1 | BMS (USA - NY) Innate Pharma (France) | Cancer - Oncology |
| 2016-10-09 | glembatumumab vedotin (CDX-011) | unresectable Stage III or IV melanoma | 2 | Celldex Therapeutics (USA - NJ) | Cancer - Oncology - Rare diseases |
| 2016-10-09 | Alimta® (pemetrexed) plus carboplatin in combination with Keytruda® (pembrolizumab) | non-small cell lung cancer (NSCLC) | 1-2 | Eli Lilly (USA - IN) Merck&Co (USA - NJ) | Cancer - Oncology |
| 2016-10-09 | nintedanib | advanced colorectal cancer | 3 | Boehringer Ingelheim (Germany) | Cancer - Oncology |
| 2016-10-09 | lirilumab or IPH2102/BMS-986015 in combination with ipilimumab (Yervoy®) | advanced solid tumors (melanoma, non-small cell lung cancer - squamous and non-squamous histology, and castrate resistant prostate cancer) | 1 | BMS (USA - NY) Innate Pharma (France) | Cancer - Oncology |
| 2016-10-09 | Opdivo® (nivolumab) | stage IV or recurrent non-small cell lung cancer | 3 | BMS (USA - NY) Ono Pharmaceutical (Japan) | Cancer - Oncology |
| 2016-10-09 | Giotrif® (afatinib) | non-small cell lung cancer (NSCLC) | 3 | Boehringer Ingelheim (Germany) | Cancer - Oncology |
| 2016-10-09 | Opdivo® (nivolumab) | recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) | 3 | BMS (USA - NY) Ono Pharmaceutical (Japan) | Cancer - Oncology |
